FluidAI Medical announced that it has acquired Emmetros Limited, the developer of the SparxConnect engagement platform, marking the company’s second acquisition as it continues to build a wider portfolio of AI-powered solutions for surgical care and postoperative recovery. The deal strengthens Stream Inara, the patient education and engagement solution within FluidAI’s platform, by integrating Emmetros’ capabilities to support continuous care before and after surgery.
Founded in 2014 and based in Canada, FluidAI Medical has focused on combining hardware, software, and real-time data to improve the full surgical continuum. The company’s Recovery Intelligence and Surgical Excellence Program, known as RISE, includes the Origin monitoring device, the Stream Care surgical expert suite, and Stream Inara for patient support after hospital discharge. By adding Emmetros, FluidAI is expanding its reach in postoperative monitoring and patient communication, enabling hospitals to provide earlier discharge while maintaining visibility into patient recovery at home.
Stream Inara plays a central role in the company’s mission to personalize patient recovery pathways. It serves as a digital management tool that guides patients before surgery and stays connected with them throughout their recovery. The platform enables the collection of patient-reported outcomes while providing ongoing education and support. FluidAI noted that the acquisition of Emmetros will help health systems increase patient throughput, streamline bed utilization, and maintain clinical assurance through continuous engagement.
Emmetros was founded in 2014 and has become known for its customizable platform supporting home care, residential care, and surgical care teams. The company’s technology is designed to improve collaboration among clinicians, patients, and family members. With Emmetros now joining FluidAI, both teams emphasized that the combination creates a stronger foundation for innovation in data-driven surgical care and enhanced patient experiences.
FluidAI Medical’s portfolio now spans real-time biochemical monitoring through its FDA-cleared Origin device, AI-based clinical risk identification, patient education and engagement tools, and clinical documentation technology. Leadership from both companies pointed to aligned missions to improve recovery outcomes, support care teams, and apply technology to enhance the entire surgical journey.
KEY QUOTES
“I could not be more pleased about this acquisition by FluidAI, which represents the best possible next chapter for our technology and our mission. Their team shares our deep commitment to improving surgical patient outcomes and care experiences through innovation, and their expertise in real-time continuous monitoring really is the perfect complement to our highly customizable and extensible patient engagement and collaboration platform.”
Mary Pat Hinton, CEO and Co-Founder, Emmetros
“Emmetros has always been dedicated to patient-centric care. Focused on solutions that empower patients and care providers, they have set the standard for how we can engage and communicate with patients.”
“This acquisition supports FluidAI’s mission in redefining the standard of surgical care to improve patient outcomes during recovery for safer early discharge after general and gastrointestinal surgery.”
Youssef Helwa, CEO, FluidAI Medical
